Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kymera Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$404.89M. For fiscal 2025 it was -$349.40M. The highest annual figure on record is -$42.21M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$349.40M | – |
| FY2024 | Dec 31, 2024 | -$261.64M | – |
| FY2023 | Dec 31, 2023 | -$165.53M | – |
| FY2022 | Dec 31, 2022 | -$161.26M | – |
| FY2021 | Dec 31, 2021 | -$100.53M | – |
| FY2020 | Dec 31, 2020 | -$46.30M | – |
| FY2019 | Dec 31, 2019 | -$42.21M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$147.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$75.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$84.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$97.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$92.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$84.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$74.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$80.76M | – |
| Q3 FY2024 | Sep 30, 2024 | -$72.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$50.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$57.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$57.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$43.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$45.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$38.63M | – |
| Q3 FY2022 | Sep 30, 2022 | -$44.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$40.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$36.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.86M | – |
See a number that looks wrong?